Lassen Therapeutics

Lassen Therapeutics is a clinical-stage biotechnology company developing antibody therapies targeting the IL-11 pathway for fibrotic diseases. Its lead asset, LASN01, is an anti-IL-11 receptor antibody currently in Phase 1 trials for Thyroid Eye Disease (TED), with plans to advance to Phase 2. The company is well-capitalized following an oversubscribed $85 million Series B financing in December 2023, which will also fund IND-enabling studies for a second program, LASN500. Lassen's strategy is centered on creating best-in-class biotherapeutics for conditions with high unmet medical need.

Industry-leading antibody technologies focused on targeting the interleukin-11 (IL-11) signaling pathway, a central mediator of fibrosis.

In Thyroid Eye Disease, Lassen competes directly with Horizon Therapeutics' blockbuster Tepezza and other emerging therapies. In Idiopathic Pulmonary Fibrosis, it would compete against established anti-fibrotics from Boehringer Ingelheim and Roche. Several other biotechs are also exploring anti-fibrotic approaches via different targets.